Lifeloc FY 2025 revenue up 6% to $9.027M; net loss widens to $2.47M on deferred tax charge

Lifeloc Technologies, Inc

Revenue $9.027M (+6% YoY); net loss $2.470M ($0.90/diluted share) vs $1.053M loss in 2024.
Gross margin stable at 40.3%; pre-tax loss improved to $1.311M from $1.405M.
Deferred tax valuation allowance increased to $1.738M (non-cash) from $187K.
SpinDetect drug analyzer: production mold fabrication started Q1 2026; first articles expected April.
New L-series breath testers (LX9, LT7) certified to AS 3547:2019; driving market penetration.

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Lifeloc Technologies, Inc reported year ended December 31, 2025 results: revenue $9.027 million, net income ($2.470) million, EPS ($0.90) per diluted share.

Period: year ended December 31, 2025
Revenue: $9.027 million
Net income: ($2.470) million
EPS: ($0.90) per diluted share
Result: reported results

Exact text from the filing

devices, has announced financial results for the 2025 fiscal year ended December 31, 2025. 2025 Financial Highlights Lifeloc Technologies reported revenue growth of 6% to $9.027 million for 2025, compared to net revenue of $8.538 million for 2024. We realized a net loss of ($2.470) million , or ($0.90) per diluted share for the year ending December 31, 2025

View on SEC.gov

1350 earnings releases filed in the last 30 days. Browse all earnings releases →

Lifeloc Technologies, Inc filing history →

Source: SEC EDGAR

accession 0001079973-26-000377

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.